Department of Biochemistry, Purdue University, West Lafayette, Indiana.
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer Res. 2019 Dec 1;79(23):6010-6023. doi: 10.1158/0008-5472.CAN-19-0615. Epub 2019 Sep 3.
Epstein-Barr virus (EBV) is a complex oncogenic symbiont. The molecular mechanisms governing EBV carcinogenesis remain elusive and the functional interactions between virus and host cells are incompletely defined. Here we present a comprehensive map of the host cell-pathogen interactome in EBV-associated cancers. We systematically analyzed RNA sequencing from >1,000 patients with 15 different cancer types, comparing virus and host factors of EBV to EBV tissues. EBV preferentially integrated at highly accessible regions of the cancer genome, with significant enrichment in super-enhancer architecture. Twelve EBV transcripts, including LMP1 and LMP2, correlated inversely with EBV reactivation signature. Overexpression of these genes significantly suppressed viral reactivation, consistent with a "virostatic" function. In cancer samples, hundreds of novel frequent missense and nonsense variations in virostatic genes were identified, and variant genes failed to regulate their viral and cellular targets in cancer. For example, one-third of patients with EBV NK/T-cell lymphoma carried two novel nonsense variants (Q322X, G342X) of and both variant proteins failed to restrict viral reactivation, confirming loss of virostatic function. Host cell transcriptional changes in response to EBV infection classified tumors into two molecular subtypes based on patterns of IFN signature genes and immune checkpoint markers, such as PD-L1 and IDO1. Overall, these findings uncover novel points of interaction between a common oncovirus and the human genome and identify novel regulatory nodes and druggable targets for individualized EBV and cancer-specific therapies. SIGNIFICANCE: This study provides a comprehensive map of the host cell-pathogen interactome in EBV malignancies..
EB 病毒(EBV)是一种复杂的致癌共生体。目前,调控 EBV 致癌的分子机制仍难以捉摸,病毒与宿主细胞的功能相互作用也不完全明确。在此,我们展示了 EBV 相关癌症中宿主细胞-病原体互作组的全面图谱。我们系统地分析了来自 15 种不同癌症类型的 1000 多名患者的 RNA 测序数据,将 EBV 病毒和宿主因子与 EBV 组织进行了比较。EBV 优先整合到癌症基因组中高度可及的区域,在超级增强子结构中存在显著富集。12 种 EBV 转录本,包括 LMP1 和 LMP2,与 EBV 再激活特征呈负相关。这些基因的过表达显著抑制了病毒的再激活,这与“抗病毒静止”功能一致。在癌症样本中,数百个新型频发错义突变和无义突变在抗病毒静止基因中被鉴定出来,并且变异基因在癌症中无法调节其病毒和细胞靶标。例如,三分之一的 EBV NK/T 细胞淋巴瘤患者携带两个新型的 (Q322X,G342X)无义变异,这两种变异蛋白均无法限制病毒的再激活,证实了抗病毒静止功能的丧失。宿主细胞对 EBV 感染的转录变化根据 IFN 特征基因和免疫检查点标志物(如 PD-L1 和 IDO1)的模式将肿瘤分为两个分子亚型。总体而言,这些发现揭示了一种常见致癌病毒与人类基因组之间新的相互作用点,并确定了新的调节节点和可针对 EBV 及癌症特异性治疗的药物靶点。